Back to All Combinations
KRAS G12D
Intermediate PrognosisGenes Involved
KRAS
Treatment Implications
Most common KRAS. MRTX1133 and other G12D inhibitors in development.
Recommended Treatments
FOLFOX + Bevacizumab
FOLFIRI + Bevacizumab
Clinical trials
Treatments to Avoid
Cetuximab
Panitumumab
Study References
MRTX1133 trials
Key Statistics
12.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Watch for G12D inhibitor approvals 2024-2025.
Information
Category: RAS Pathway
Evidence Level: Level 2A
Last Updated: Dec 7, 2025
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.